Previous close | 2.8400 |
Open | 2.8900 |
Bid | 2.9100 x 100 |
Ask | 2.9400 x 100 |
Day's range | 2.8600 - 3.0300 |
52-week range | 2.7000 - 6.2500 |
Volume | |
Avg. volume | 372,258 |
Market cap | 142.807M |
Beta (5Y monthly) | -0.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.4400 |
Earnings date | 25 Mar 2024 - 29 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 6.07 |
Following incubation with HCA Healthcare EDs, Augmedix announces the general availability of Augmedix Go in emergency departmentsSAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced the general availability of Augmedix Go for emergency departments (EDs), marking the launch of the industry’s first fully-automated, generative AI (GenAI) powered medical documentation product for EDs across the cou
On April 11, 2024, Ian Shakil, Chief Strategy Officer of Augmedix Inc (NASDAQ:AUGX), sold 92,787 shares of the company.
On April 8, 2024, Ian Shakil, Chief Strategy Officer of Augmedix Inc (NASDAQ:AUGX), sold 89,167 shares of the company.